No Data
No Data
ChengDu ShengNuo Biotec Unit Signs Up to 350 Million-Yuan Peptide Supply Contract
Sanon Bio (688117.SH): Subsidiary signs GLP-1 peptide active pharmaceutical ingredient sales contract not exceeding 0.35 billion yuan
Shengnuo Biology (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd. ("Shengnuo...
Shengnuo Biology (688117.SH): signed overseas "investment cooperation agreement".
On September 6, Gelonghui announced that in order to improve the company's overseas strategic layout, promote communication and cooperation with overseas markets, further expand overseas business, and enhance the company's overall competitiveness, the company intends to sign an Investment Cooperation Agreement with AfricaBioChemCo.Ltd in Tanzania. The company plans to invest 30 million RMB and subscribe for 22.78% equity of AfricaBioChemCo.Ltd in the United Republic of Tanzania (referred to as "Tanzania") as the target company. This is the company's overseas investment.
Lepu Medical Technology plans to reduce its shareholding by no more than 2% in Shengnuo Biotechnology (688117.SH).
On September 3, J.LUNGHUI: | Shenno Biology (688117.SH) Announced that the company recently received a notification letter from shareholder Lepu Medical Technology Regarding the shareholding plan, Lepu Medical Technology intends to reduce its total holdings in the company by no more than 2,240,000 shares, i.e. not more than 2% of the total share capital, due to the shareholder's own fund needs. The portion to be reduced through centralized bidding will be carried out within 3 months after 15 trading days from the date of this announcement, and the total number of shares to be reduced in any 90 consecutive natural days shall not exceed 1% of the total number of company shares.
ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) 37% Jump Shows Its Popularity With Investors
Private Companies Are ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥363m Last Week
No Data
No Data